denali dnl343 news - Search News

ALS, Denali Therapeutics

Outsourcing-pharma · 2d

Denali Therapeutics’ ALS drug fails to improve function and survival in phase 2/3 trial

Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future analysis.

GlobalData on MSN · 2d

Denali Therapeutics’ ALS therapy fails to meet primary endpoint in Phase II/III trial

Denali Therapeutics has reported that its Phase II/III HEALEY ALS Platform trial of DNL343 for ALS failed to meet its primary endpoint.

MarketWatch · 3d

Denali Therapeutics Says ALS Trial Didn't Meet Endpoints

Denali Therapeutics said the latest trial of its treatment for amyotrophic lateral sclerosis, or ALS, didn't meet its primary or secondary endpoints after 24 weeks. The biotechnology company said Monday that DNL343 didn't meet the primary endpoint of slowing disease progression as compared with a placebo.

15h

Why biotech startup Tenvie sees promise in drugs from founders' old company

About a year ago, Tenvie President and Chief Scientific Officer Tony Estrada approached Denali CEO Ryan Watts and others in ...

ALS News Today15h

DNL343, fosigotifator fail HEALEY platform trial’s main goal in ALS

DNL343 and fosigotifator are made to activate the ISR pathway protein eIF2B, but both failed to slow ALS progression in the ...

3d

Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial

Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results